- Home
- LGHL vs REVB Comparison
LGHL vs REVB Comparison
Compare LGHL & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGHL
- REVB
- Stock Information
- Founded
- LGHL 2015
- REVB 2020
- Country
- LGHL Singapore
- REVB United States
- Employees
- LGHL N/A
- REVB N/A
- Industry
- LGHL Investment Bankers/Brokers/Service
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- LGHL Finance
- REVB Health Care
- Exchange
- LGHL Nasdaq
- REVB Nasdaq
- Market Cap
- LGHL 1.4M
- REVB 1.4M
- IPO Year
- LGHL N/A
- REVB N/A
- Fundamental
- Price
- LGHL $0.18
- REVB $0.34
- Analyst Decision
- LGHL
- REVB
- Analyst Count
- LGHL 0
- REVB 0
- Target Price
- LGHL N/A
- REVB N/A
- AVG Volume (30 Days)
- LGHL 3.4M
- REVB 1.7M
- Earning Date
- LGHL 12-24-2024
- REVB 11-08-2024
- Dividend Yield
- LGHL N/A
- REVB N/A
- EPS Growth
- LGHL N/A
- REVB N/A
- EPS
- LGHL N/A
- REVB N/A
- Revenue
- LGHL $18,678,142.00
- REVB N/A
- Revenue This Year
- LGHL N/A
- REVB N/A
- Revenue Next Year
- LGHL N/A
- REVB N/A
- P/E Ratio
- LGHL N/A
- REVB N/A
- Revenue Growth
- LGHL N/A
- REVB N/A
- 52 Week Low
- LGHL $0.13
- REVB $0.32
- 52 Week High
- LGHL $1.55
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- LGHL 41.55
- REVB 27.29
- Support Level
- LGHL $0.13
- REVB $0.32
- Resistance Level
- LGHL $0.17
- REVB $0.47
- Average True Range (ATR)
- LGHL 0.02
- REVB 0.08
- MACD
- LGHL -0.00
- REVB -0.02
- Stochastic Oscillator
- LGHL 33.33
- REVB 3.40
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).